NEW YORK (Reuters Health) - A dose of a chemical found in broccoli and other vegetables may improve the behavioral and social symptoms of autism in young men, according to a new small study.
But people would have to eat a possibly unrealistic amount of broccoli and other vegetables to reach the dose of the molecule - known as sulphoraphane - used in the new study, the lead researcher told Reuters Health.
“Our extract product we used is not on the market,” Dr. Andrew W. Zimmerman said by phone. “There are other things like it but in different forms.”
Sulphoraphane is found in cruciferous vegetables like broccoli, cauliflower and cabbage, but more so in the raw vegetables than cooked. Previous studies have found that it inhibits some bacterial growth and may slow the growth of some cancers.
For the new study, the researchers divided 40 young men with moderate to severe autism spectrum disorder into two groups. One group received varying daily doses of broccoli sprout extract. The others received an inert capsule, known as a placebo.
The researchers and caregivers, who did not know which men received extract and which received placebo, regularly rated the young men’s behavior and social interaction after the trial began. They also rated the participants a month after the trial ended.
The men were rated on irritability, tiredness, repetitive movements, hyperactivity, communication, motivation and mannerisms.
The average scores on both scales were better from four weeks onward for the 26 young men assigned to sulphoraphane compared to the 14 in the placebo group, Zimmerman and colleagues reported in the Proceedings of the National Academy of Sciences.
Of the 26 young men given sulphoraphane, 17 were judged to have improved in behavior, social interaction and calmness by caregivers and staff. There was little change among those in the placebo group.
Sulphoraphane didn’t work for everyone, but for about two-thirds of the group there was a noticeable improvement, Zimmerman said.
“We could tell who was on it and parents could too,” Zimmerman said. “There are several families who just can’t stop praising it.”
Most of the improvements had disappeared by one month after treatment, however.
The researchers write that young people with autism tend to make more eye contact and have improved speech when they have fevers. They suggest that sulphoraphane “stresses” the body like a fever with few or no side effects.
“Stress is not all bad,” Zimmerman said, noting that it can change the way some genes, potentially those governing autism, are expressed.
The participants in the new study were closely monitored and did not suffer from fever.
But most of what is known about the possible effects of fever on autism is based only on anecdotes and any connection is tentative at this point, said Rebecca J. Schmidt, of the department of public health sciences at the School of Medicine at the University of California, Davis.
“Our group has been interested in studying the link between maternal cruciferous vegetable intake and potentially reduced risk of autism in the child,” said Schmidt, who was not involved with the new study.
If individuals with autism eat these vegetables, it should not do a lot of harm and could have benefits, she told Reuters Health by phone.
These results will have to be replicated before they can be confirmed, and it may turn out that this specific broccoli extract isn’t the most effective form for people with autism, Zimmerman said.
Further studies are needed to assess whether the link would be the same for women and younger children, Schmidt said, adding that studies are also needed on whether it may play a role in autism prevention.
Zimmerman is with the Lurie Center for Autism in Lexington, Massachusetts, and the Massachusetts General Hospital for Children and Harvard Medical School in Boston. He was affiliated with The Johns Hopkins University School of Medicine in Baltimore when he collaborated with Dr. Paul Talalay, the first person to isolate sulphoraphane, on the design of the trial.
Several clinical trials with sulphoraphane are currently underway, examining its effects on conditions such as asthma, prostate cancer and schizophrenia, according to Clinicaltrials.gov.
SOURCE: bit.ly/1Ced2dB PNAS, online October 13, 2014.